After all these correlations with T-cell infiltration, interferon-γ, HPV status, and mutational burden, it follows that GITR and OX40 methylation and mRNA expression levels can be used as a predictive biomarker for identifying HNSCC patients who would benefit from adjuvant immunotherapy [50]. The gene discussed is TNFRSF18; the disease is head and neck squamous cell carcinoma.